Contribute Try STAT+ Today

Novartis

Most Read

Novartis campus

Business By Charles Piller

Autofocus contact lens being developed by Verily and Alcon suffers delay

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: The ‘Right to Try’ movement is spreading to Canada

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Drug makers warn German price controls will threaten access

Prescription Medicine Bottles

Pharmalot By Ed Silverman

Which drug makers do a good job getting poor patients access to their medicines?

Pharmalot By Ed Silverman

Novartis has a history of charging high prices for drugs in Colombia

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Feds probe Express Scripts’s relationship with pharma

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: To avoid scandal, Novartis CEO advises companies not to hire rulebreakers

Pharmalot By Ed Silverman

Novartis to pay $35 million to settle charges of illegally promoting a drug for infants

All Coverage

Pharmalot By Ed Silverman

European agency gives nod to Novartis over use of toxic chemical in drugs

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: India plans tougher penalties for bribing doctors

advertisement

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Novartis dissolves its CAR-T therapies unit

Pharmalot By Ed Silverman

Novartis continues to face a bribery probe in Turkey, after all

NJ: Corporations In New Jersey

Pharmalot By Ed Silverman

Novartis execs in Korea are indicted for bribing doctors

Pharmalot By Ed Silverman

State Department accused of interfering with efforts for affordable medicines

Entresto Ad

Business By Rebecca Robbins

Republican convention viewers sure saw a lot of drug ads

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Novartis stops making TB drugs in Pakistan, prompting fear of a health crisis

Pharmalot By Ed Silverman

Novartis buries news that the FDA rebuffed its biosimilar drug

Pharmalot By Ed Silverman

Bristol-Myers pays $30 million to settle kickback charges

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Novartis to spend $200 million to promote its flagging heart drug

Pharmalot By Ed Silverman

Drug and device makers paid $6.5 billion to docs and teaching hospitals last year

Harvard Pilgrim Patient Outcomes

Pharmalot By Ed Silverman

Another big insurer will pay for key drugs based on patient outcomes

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: India revising laws to upgrade drug safety

Novartis Colombia

The Pharmalot View By Ed Silverman

Novartis, Colombia face off over cancer drug cost

Pharmalot By Ed Silverman

Colombia plans to unilaterally lower the cost of a Novartis cancer drug

Pharmalot By Ed Silverman

Bernie Sanders accuses US Trade Rep of intimidating Colombia over Novartis patent